Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation

Circulation Research

Volumn 71, Issue 2, 1992, Pages 271-287

  Wang, Zhiguo ^b   Pagé, Pierre ^b   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE

Author keywords

Action potential duration; Antiarrhythmic drugs; Arrhythmia mechanisms; Atrial fibrillation; Electrocardiography; Flecainide; Heart rate; Refractory period

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; EXPERIMENTAL MODEL; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION SYSTEM; HEART MUSCLE POTENTIAL; HEART RATE; MALE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; REFRACTORY PERIOD; RELIABILITY; REPRODUCIBILITY; VAGUS NERVE;

ACTION POTENTIALS; ANIMAL; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; COMPARATIVE STUDY; DOGS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; FEMALE; FLECAINIDE; HEART ATRIUM; HEART RATE; MALE; RANDOM ALLOCATION; SOFTWARE; SUPPORT, NON-U.S. GOV'T; VAGUS NERVE;

EID: 0026635429     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.71.2.271     Document Type: Article

References (74)

1. Herre JM, Scheinman MM: Supraventricular tachycardia, in Parmley WW, Chatterjee K, Cheitlin MD, Karliner JS, Rapaport E, Scheinman MM (eds): Cardiology: Physiology, Pharmacology, Diagnosis. Philadelphia, J.B. Lippincott Co., 1988, pp 1-19
2. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL: Propafenone for suppression of refractory symptomatic atrial fibrillation. (abstract) Circulation 1987;76(suppl IV):IV-68
3. Hammill S, Wood D, Sugrue D, Gersh B, Osborn M, Holmes D: Propafenone for chronic treatment of paroxysmal atrial fibrillation. (abstract) Circulation 1985;72(suppl III):III-171
4. Kerr CR, Mason MA, Chung DC: Propafenone: An effective drug for prevention of recurrent atrial fibrillation. (abstract) Circulation 1985;72(suppl III):III-171
5. Chouty F, Coumel P: Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 1988;62:35D-37D
6. Kappenberger LJ, Fromer MA, Shenasa M, Gloor HO: Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 1985;8:321-326
7. Goy JJ, Maendly R, Grbic M, Finci L, Sigwart U: Cardioversion with flecainide in patients with atrial fibrillation of recent onset. Eur J Clin Pharmacol 1985;27:737-738
8. Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV: Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987;59:1337-1341
9. Crijns HJGM, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI: Acute conversion of atrial fibrillation to sinus rhythm: Clinical efficacy of flecainide acetate: Comparison of two regimens. Eur Heart J 1988;9:634-638
10. Goy JJ, Kaufmann U, Kappenberger L, Sigwart U: Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988;62:38D-40D
11. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U: Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-498
12. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG: Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989;63: 693-696
13. van Gelder I, Crijns HJ, van Gilst WH, Lie KI: Efficacy of flecainide to maintain sinus rhythm after cardioversion of chronic atrial fibrillation and flutter. (abstract) Circulation 1988;78(suppl II):II-626
14. Rasmussen K, Andersen A, Abrahamsen AM, Overskeid K, Bathen J: Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. (abstract) Eur Heart J 1988;9(suppl I):I-52
15. Marchlinski FE: Propafenone: New therapy for a tough, old arrhythmia. J Am Coll Cardiol 1988;12:1012-1014
16. Campbell TJ: Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983;17:344-352
17. Harrison DC: Antiarrhythmic drug classification: New science and practical applications. Am J Cardiol 1985;56:185-187
18. Zipes DP: Genesis of cardiac arrhythmias, in Braunwald E (ed): Heart Disease, ed. 3. Philadelphia, WB Saunders Co, 1988, pp 581-620
19. Bigger JT, Hoffman BF: Antiarrhythmic drugs, in Gilman AG, Goodman LL, Kall TW, Murad F (eds): The Pharmacological Basis of Therapeutics, ed. 7. New York, Macmillan Publishing Co., 1985, pp 748-783
20. Moe GK, Rheinboldt WC, Abildskov JA: A computer model of atrial fibrillation. Am Heart J 1964;67:200-220
21. Abildskov JA, Millar K, Burgess MJ: Atrial fibrillation. Am J Cardiol 1971;28:263-267
22. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J: Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology and Arrhythmias. New York, Grune & Stratton, Inc, 1985, pp 265-276
23. Chen PS, Smith WM, Greer S, Wharton JM, Vidaillet HJ Jr, Ideker RE: Activation patterns during electrically induced atrial fibrillation in humans. (abstract) Circulation 1986;74(suppl II):II-483
24. Wang Z, Pelletier LC, Talajic M, Nattel S: Effects of flecainide and quinidine on human atrial action potentials: Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 1990;82:274-283
25. Wang Z, Villemaire C, Pagé P, Nattel S: Mechanism of flecainide's beneficial actions in experimental atrial fibrillation. (abstract) Circulation 1990;82(suppl III):III-98
26. Talajic M, Villemaire C, Nattel S: Electrophysiological effects of α-adrenergic stimulation. PACE 1990;13:578-582
27. Nattel S, Jing W: Rate-dependent changes in intraventricular conduction produced by procainamide in anesthetized dogs: A quantitative analysis based on the relation between phase 0 inward current and conduction velocity. Circ Res 1989;65:1485-1498
28. Gallagher JJ, Kasell JH, Cox JL, Smith WM, Ideker RE, Smith WM: Techniques of intraoperative electrophysiologic mapping. Am J Cardiol 1982;49:221-240
29. Gallagher JJ, Kasell J, Sealy WC, Pritchett ELC, Wallace AG: Epicardial mapping in the Wolff-Parkinson-White syndrome. Circulation 1978;57:854-866
30. Alessi R, Nusynowitz M, Abildskov JA, Moe GK: Nonuniform distribution of vagal effects on the atrial refractory period. Am J Physiol 1958;192:406-410
31. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410
32. Goldstein A: Biostatistics - An Introductory Text. New York, MacMillan Publishers, 1964
33. Wiener N, Rosenblueth A: The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle. Arch Inst Cardiol Mex 1946;16:205-265
34. Goodman D, Van der Steen ABM, Van Dam RT: Endocardial and epicardial activation pathways of the canine right atrium. Am J Physiol 1971;220:1-11
35. El-Sherif N, Smith RA, Evans K: Canine ventricular arrhythmias in the late myocardial infarction period: 8. Epicardial mapping of reentrant circuits. Circ Res 1981;49:255-265
36. Mehra R, Zeiler RH, Gough WB, El-Sherif N: Reentrant ventricular arrhythmias in the late myocardial infarction period: 9. Electrophysiologic-anatomic correlation of reentrant circuits. Circulation 1983;67:11-24
37. Kirchhof C, Wijffels M, Brugada J, Planellas J, Allessie M: Mode of action of a new class 1C drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol 1991;17:116-124
38. O'Hara G, Talajic M, Villemaire C, Nattel S: Effects of flecainide on atrial refractoriness, atrial repolarization, and atrioventricular nodal conduction in anesthetized dogs. J Am Coll Cardiol (in press)
39. Feld GK, Venkatesh N, Singh BN: Pharmacologic conversion and suppression of experimental canine atrial flutter: Differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation 1986;74:197-204
40. Boyden PA: Effects of pharmacologic agents on induced atrial flutter in dogs with right atrial enlargement. J Cardiovasc Pharmacol 1986;8:170-177
41. Wu KM, Hoffman BF: Effect of procainamide and N-acetylprocainamide on atrial flutter: Studies in vivo and in vitro. Circulation 1987;76:1397-1408
42. Feld GK, Venkatesh N, Singh BN: Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: Significance of changes in refractoriness and conduction. J Cardiovasc Pharmacol 1988;11:573-580
43. Spinelli W, Hoffman BF: Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res 1989;65:1565-1579
44. Frame LH, Page RL, Boyden PA, Fenoglio JJ, Hoffman BF: Circus movement in the canine atrium around the tricuspid ring during experimental atrial flutter and during reentry in vitro. Circulation 1987;76:1155-1175
45. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J: Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation, in Zipes DP, Jalife J (eds): Cardiac Electrophysiology and Arrhythmias. Orlando, Fla, Grune & Stratton, Inc, 1985, pp 265-276
46. Mines GR: On dynamic equilibrium in the heart. J Physiol 1913; 46:349-383
47. Lewis T: The Mechanism and Graphic Registration of the Heart Beat, ed 3. London, Shaw & Sons, 1925, pp 319-324
48. Allessie MA, Bonke FIM, Schopman FJG: Circus movement in rabbit atrial muscle as a mechanism of tachycardia: III. The "leading circle" concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977;41:9-18
49. Smeets JLRM, Allessie MA, Lammers WJEP, Bonke FIM, Hollen J: The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium. Circ Res 1986;58:96-108
50. k, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990;82:289-293
51. Colatsky TJ, Follmer CH, Starmer CF: Channel specificity in antiarrhythmic drug action: Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82:2235-2242
52. Fermini B, Nattel S: Differential effects of flecainide and quinidine on repolarizing currents in dog atrial myocytes. (abstract) Circulation 1990;82(suppl III):III-526
53. Shibata EF, Drury T, Refsum H, Aldrete V, Giles W: Contributions of a transient outward current to repolarization in human atrium. Am J Physiol 1989;257:H1773-H1781
54. Wang Z, Fermini B, Nattel S: Mechanisms of tachycardia-dependent atrial APD prolongation by flecainide in dogs. (abstract) Can J Cardiol 1991;7(suppl A):123A
55. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O: Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: Importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990;16:1408-1414
56. Wiseman MN, Nathan AW: Intravenous flecainide versus intravenous disopyramide in the reversion of atrial fibrillation. (abstract) J Am Coll Cardiol 1989;13:165A
57. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M: Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-338
58. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE: Atrial enlargement as a consequence of atrial fibrillation. Circulation 1990;82:792-797
59. Ten Eick RE, Singer DH: Electrophysiological properties of diseased human atrium: I. Low diastolic potential and altered cellular response to potassium. Circ Res 1979;44:545-557
60. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR, Rosen MR: The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983;52:188-199
61. Murdock C, Kyles A, Yeung-Lai-Wah J, Qi A, Kerr CR: Conversion of atrial fibrillation to flutter with propafenone. (abstract) Clin Invest Med 1989;12(suppl C):C45
62. Feld GK, Chen PS, Nicod P, Fleck RP, Mezer D: Atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol 1990;66:378-383
63. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R: The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172
64. Hondeghem LM, Snyders DJ: Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690
65. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412
66. Nattel S, Pedersen DH, Zipes DP: Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981;15:80-85
67. Lederman SN, Wenger TL, Bolster DE, Strauss HC: Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. J Cardiovasc Pharmacol 1989;13:541-546
68. Nattel S, Waters D: What is an antiarrhythmic drug? From clinical trials to fundamental concepts. Am J Cardiol 1990;66:96-100
69. Morganroth J, Goin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A metaanalysis. Circulation 1991;84:1977-1983
70. Coumel P, Leclercq JF, Attuel P, Lavallée JP, Flammang D: Autonomic influences in the genesis of atrial arrhythmias: Atrial flutter and fibrillation of vagal origin, in Narula DS (ed): Cardiac Arrhythmias - Electrophysiology, Diagnosis and Management. Baltimore, Md, Williams and Williams, 1979, pp 243-255
71. Pagé PL, Hassanalizadeh, Cardinal René: Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dogs with sterile pericarditis. Can J Physiol Pharmacol 1991;69:15-24
72. Campbell TJ: Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983;17:344-352
73. Ranger S, Talajic M, Lemery R, Roy D, Villemaire C, Nattel S: Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans. Circulation 1991;83:1987-1994
74. Campbell TJ: Importance of physio-chemical properties in determining the kinetics of the effects of class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle. Br J Pharmacol 1983;80:33-40